[10-Q/A] Nukkleus Inc. Warrants Amended Quarterly Earnings Report

Rhea-AI Filing Summary

Universal Insurance Holdings, Inc. (NYSE: UVE) filed an 8-K to disclose a shareholder-friendly capital action and upcoming investor events.

• Dividend declaration: The Board approved a $0.16 per-share cash dividend on common stock. The payout date is August 8, 2025; shareholders must own shares as of the August 1, 2025 record date.
• Earnings timetable: First-quarter FY25 results will be released on July 24, 2025. Management will host an earnings call the following day, July 25, 2025.
• No other material transactions, financial statements, or guidance updates were included in the filing.

The disclosure is routine but signals continued cash returns to shareholders and provides the market with key dates for the forthcoming earnings cycle.

Positive

• $0.16 per-share cash dividend demonstrates continued shareholder returns and management confidence.
• Earnings release and call dates give investors clarity for upcoming financial updates.

Negative

• None.

Insights

Financial Analyst

TL;DR: Routine 8-K reveals $0.16 dividend and sets Q1 earnings dates; moderately positive for income investors.

The cash dividend affirms UVE’s willingness to return capital, suggesting adequate liquidity and continuing profitability in a challenging Florida P&C market. At $0.16 per share, the annualized payout (if unchanged) would be $0.64, but the filing does not provide historical context, so comparability is limited. Investors now have clear timelines for Q1 results and the conference call, which should offer insight into loss trends and reinsurance costs. Overall impact is modest; the announcement does not alter the investment thesis but supports a stable income narrative.

Income-Focused Portfolio Manager

TL;DR: Dividend confirms steady cash flow; news is incremental, not transformative.

A declared payout ahead of earnings conveys management’s confidence in near-term cash generation. However, without prior dividend data or payout ratio, it’s difficult to judge growth. The information is useful for positioning ahead of the July 24 earnings release but lacks the granularity (combined ratio, catastrophe exposure) needed to drive portfolio rebalancing. I view the disclosure as neutral to slightly positive and not materially impactful on valuation.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q/A

Amendment No. 1

☒ QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2025

OR

☐ TRANSITION REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________ to __________

Commission file number: 001-39341

Nukkleus Inc.

(Exact name of registrant as specified in its charter)

Delaware		38-3912845
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification No.)

575 Fifth Ave, 14^th Floor, New York, New York 10017

(Address of principal executive offices, including zip code)

212-791-4663

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		NUKK		The Nasdaq Stock Market LLC
Warrants, each warrant exercisable for one Share of Common Stock for $92.00 per share		NUKKW		The Nasdaq Stock Market LLC

Securities registered under Section 12(g) of the Exchange Act: None

Indicate by check mark whether the registrant (1) has filed all reports required by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☐    No ☒

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒   No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐    No ☒

State the number of shares outstanding of each of the issuer’s classes of common equity, as of the latest practicable date.

Class		Outstanding July 3, 2025
Common Stock, $0.0001 par value per share		5,360,844  shares

EXPLANATORY NOTE

On May 23, 2025, Nukkleus Inc., filed its quarterly report on Form 10-Q for the period ended March 31, 2025 (the “Original Filing”). The Company is filing this Amendment No. 1 to the Original Filing (the “Amendment”) solely for the purpose of correcting the disclosure in Item 4—Controls and Procedures of the Original Filing to include a clear definitive statement disclosing management’s conclusion on the lack of effectiveness of the Company’s disclosure controls and procedures.

In addition, in connection with the filing of this Amendment and pursuant to SEC rules and regulations, we are including with this Amendment certain currently dated certifications. Accordingly, Item 6 of Part II has also been amended to reflect the filing of these currently dated certifications.

This Amendment does not attempt to modify or update any other disclosures set forth in the Original Filing. Additionally, this Amendment speaks as of the filing date of the Original Filing and does not update or discuss any other Company developments subsequent to the date of the Original Filing.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls

Our management conducted an evaluation, with the participation of its Chief Executive Officer, who is also its Chief Financial Officer, of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a—15(e) and 15d—15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”)) as of the end of the period covered by this Quarterly Report on Form 10-Q. Based upon that evaluation, the Chief Executive Officer concluded that our disclosure controls and procedures were not effective in reporting, on a timely basis, information required to be disclosed by us in the reports we file or submit under the Exchange Act, because of material weaknesses in internal control over financial reporting as of March 31, 2025, as described below.

Plan of Remediation of Material Weaknesses in Internal Control Over Financial Reporting 

Following the identification and communication of the material weakness described above, management commenced remediation actions relating to this material weakness beginning in the fourth quarter of fiscal year 2024, as follows:

● We are utilizing the services of external consultants for non-routine and/or technical accounting issues as they arise.

● We are expanding and improving our review process for complex accounting transactions. We plan to further improve this process by enhancing access to accounting literature, identification of third-party professionals with whom to consult regarding complex accounting applications and consideration of additional staff with the requisite experience and training to supplement existing accounting professionals.

● We are implementing enhancements and process improvements, including the design and implementation of well-defined controls and related control attributes

The material weaknesses identified above will not be considered fully remediated until these additional controls and procedures have operated effectively for a sufficient period of time and management has concluded, through testing, that these controls are effective. Our management will monitor the effectiveness of our remediation plans and will make changes management determines to be appropriate. If not remediated, these material weaknesses could result in material misstatements to our annual or interim consolidated financial statements that may not be prevented or detected on a timely basis or result in a delayed filing of required periodic reports. If we are unable to assert that our internal control over financial reporting is effective, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could be adversely affected, and we could become subject to litigation or investigations by Nasdaq, the SEC, or other regulatory authorities, which could require additional financial and management resources.

Notwithstanding the above, management believes that the consolidated financial statements included in this Quarterly Report on Form 10-Q, fairly present, in all material respects, our financial condition, results of operations and cash flows for the periods presented in accordance with generally accepted accounting principles.

Limitations on the Effectiveness of Controls

A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resources constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control.

The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can only be reasonable assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, control may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

Changes in Internal Control over Financial Reporting.

There were no changes in our internal control over financial reporting, known to the Chief Executive Officer that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. 

1

Item 6. Exhibits

The following exhibits are incorporated into this Form 10-Q Quarterly Report:

				Incorporated by Reference
Exhibit		Description		Schedule/ Form		Exhibits		Filing Date
31.1		Rule 13a-14(a) Certification of the Chief Executive Officer and Principal Financial Officer
32.1		Section 1350 Certification of Chief Executive Officer and Principal Financial Officer
101.INS		Inline XBRL Instance Document.
101.SCH		Inline XBRL Taxonomy Extension Schema Document.
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104		Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	NUKKLEUS INC.
	By:	/s/ Menachem Shalom
Dated: July 8, 2025		Menachem Shalom
		Chief Executive Officer (Principal Executive Officer), and Principal Financial and Accounting Officer and Director

3

0001787518 true Q1 --09-30 0001787518 2025-01-01 2025-03-31 0001787518 nukk:CommonStock00001ParValuePerShareMember 2025-01-01 2025-03-31 0001787518 nukk:WarrantsEachWarrantExercisableForOneShareOfCommonStockFor9200PerShareMember 2025-01-01 2025-03-31 0001787518 2025-07-03 xbrli:shares

FAQ

How much is Universal Insurance Holdings' (UVE) new dividend?

The Board declared a $0.16 cash dividend per share.

When is the dividend record date for UVE shareholders?

Shareholders must be on record by August 1, 2025 to receive the dividend.

When will the $0.16 dividend be paid?

The dividend is payable on August 8, 2025.

When will UVE release its first-quarter 2025 earnings?

Universal Insurance Holdings will publish Q1 results on July 24, 2025.

What date is the earnings conference call for UVE?

Management will host the call on July 25, 2025.